Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.

Hunt, Thomas; Kaplan, Nachum; Hafkin, Barry

Hunt, Thomas; Kaplan, Nachum; Hafkin, Barry.

Affiliation

Hunt T; a Pharmaceutical Product Development Inc , Austin , TX , USA.
Kaplan N; b Affinium Pharmaceuticals, Inc.
Hafkin B; b Affinium Pharmaceuticals, Inc.

J Chemother ; 28(3): 164-71, 2016 Jun.

Article in En | MEDLINE | ID: mdl-26431470

Subject(s)

Anti-Bacterial Agents/adverse effects; Anti-Bacterial Agents/pharmacokinetics; Benzofurans/adverse effects; Benzofurans/pharmacokinetics; Pyrones/adverse effects; Pyrones/pharmacokinetics; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents/administration & dosage; Area Under Curve; Benzofurans/administration & dosage; Cohort Studies; Cross-Over Studies; Fasting; Female; Healthy Volunteers; Humans; Male; Pyrones/administration & dosage; Tablets; Tissue Distribution; Young Adult

Key words

AFN-1252; FabI inhibitor; Immediaterelease; Multiple dose; Pharmacokinetics; Phase I; Safety; Staphylococcus aureus

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrones / Benzofurans / Anti-Bacterial Agents Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: J Chemother Journal subject: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Year: 2016 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google